This study further supports the effectiveness of camrelizumab in second-line treatment for advanced NSCLC, particularly in patients with PD-L1 positivity.[34] A retrospective cohort study evaluating this combination as second-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) demonstrated a pronounced and statistically significant improvement in PFS compared to chemotherapy (median PFS: 7.0 vs 3.0 months; HR: 0.34, 95% CI: 0.15–0.77; P < .001). The gene discussed is CD274; the disease is small cell lung carcinoma.